Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Hologic

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022

Hologic's Return On Capital Employed Overview

Hologic's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters.

Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

Hologic Inc (NASDAQ:HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily drove a fall in sales. Hologic's global diagnostics business posted revenues of $987.1 million, down 7%. Diagnostics revenues excluding COVID-19 revenues…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current…

Expert Ratings for Hologic

Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Death Cross Looms Over Hologic Investors

Death Cross Looms Over Hologic Investors

If history is any guide, there may be trouble ahead for shares of Hologic (NASDAQ:HOLX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Analyst Ratings For Hologic

Analyst Ratings For Hologic

Over the past 3 months, 5 analysts have published their opinion on Hologic (NASDAQ:HOLX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Looking Into Hologic's Return On Capital Employed

Looking Into Hologic's Return On Capital Employed

According to Benzinga Pro, during Q1, Hologic (NASDAQ:HOLX) earned $499.20 million, a 51.82% increase from the preceding quarter. Hologic also posted a total of $1.47 billion in sales, a 11.69% increase since Q4.

Hologic Q1 FY22 Sales Decline 9% On Lower COVID-19 Assay Sales; Issues Upbeat FY22 Outlook

Hologic Q1 FY22 Sales Decline 9% On Lower COVID-19 Assay Sales; Issues Upbeat FY22 Outlook

Hologic Inc (NASDAQ: HOLX) reported

Hologic: Q1 Earnings Insights

Hologic: Q1 Earnings Insights

Hologic (NASDAQ:HOLX) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

1 2

Organisations

Advanced Micro Devices

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play